TAG:
biopsies
October 29, 2012 “Intelligence: Late Breaking Lab News”
OURLab and its parent company, Prost Data, Inc., of Nashville, Tennessee, entered into an agreement to be sold to Opko Health Inc., of Miami, Florida. The purchase price of $40 million will be paid as $9.4 million in cash and $30.6 million in stock. …
Med Tech Finds “Grace” Aboard Lab of Mercy Ship
CEO SUMMARY: One intrepid medical technologist has spent almost two decades in volunteer service working in the clinical laboratories of hospital ships operated by Mercy Ships International. As the world’s largest hospital ship, the Africa Mercy contains six operating rooms, a 78-bed IC…
Labs Have Questions about Prostate Biopsy Policy
CEO SUMMARY: How will pathology laboratories respond to the publication of revised policies in how laboratories should file Medicare Part B claims for prostate biopsies? Not only will there be a sharp drop in the reimbursement paid for a 12-core prostate biopsy, but labs may be at increas…
In Medicare Bull’s Eye: Lab Test Reimbursement
YOU CAN CONSIDER THIS ISSUE OF THE DARK REPORT TO BE an early warning of the escalating effort by public and private payers to rein in the “soaring cost” of clinical laboratory testing and anatomic pathology services. The intelligence briefings you will read on the following pag…
Changed Medicare Policy Adds to Regulatory Risk
CEO SUMMARY: When Medicare’s National Correct Coding Initiative (NCCI) manual took effect on January 1, 2012, it contained a significant change in how prostate biopsy claims are to be coded. This change was widely overlooked by the pathology profession and even dismissed entirely for it…
Lawyer Advises on Risk Of Prostate Biopsy Audits
CEO SUMMARY: For labs currently processing prostate biopsy cases with five or more cores and for those pathologists interpreting those cases, there is a lack of clarity about new Medicare policies. As one example, risk of an audit is significant because of recent guidance issued by one Me…
Prostate Biopsy Claims Affected by Policy Change
CEO SUMMARY: Quietly, with no fanfare and little advance public notice, the Medicare program is taking steps to change reimbursement policy for prostate biopsies. On August 7, 2012, Palmetto GBA adopted the new policy published on January 1, 2012, by the National Correct …
Indiana Clinical Lab Taps Data to Improve Service to Doctors
CEO SUMMARY: Business intelligence is on the verge of becoming the next “big thing” in clinical laboratory management. Lab teams are using real-time data dashboards to quickly identify problems and take proactive steps to raise service levels to clients. South Bend Medical Foundation …
MD Self-Referral Issues Target of Utilization Study
CEO SUMMARY: When it comes to the in-office ancillary service (IOAS) exception to physician self-referral, the issue of in-clinic pathology services has become a hot potato. Publication in Health Affairs of a study of urologists’ self-referral of their patients for anatomic pathology se…
MedTox, Cleveland Clinic Labs, Apollo PACS, Dell, British Columbia Health
GENOME SEQUENCING TO BE OFFERED BY NORWAY IN NATIONAL HEALTH PLAN HERE’S A MILESTONE ON THE PATH TO PERSONALIZED MEDICINE. Norway is the first nation to announce that its national health system will incorporate whole genome sequencing. Cancer is the target of Norway’s f…
CURRENT ISSUE
Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.